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Abstract
Background: Several lines of evidence support the involvement of the lectin pathway of complement (LP) in the
pathogenesis of acute ischemic stroke. The aim of this multicenter observational study was to assess the prognostic
value of different circulating LP initiators in acute stroke.
Methods: Plasma levels of the LP initiators ficolin-1, -2, and -3 and mannose-binding lectin (MBL) were measured
in 80 stroke patients at 6 h only and in 85 patients at 48 h and later. Sixty-one age- and sex-matched healthy
individuals served as controls. Stroke severity was measured on admission using the National Institutes of Health
Stroke Scale (NIHSS). The outcome was measured at 90 days by the modified Rankin Scale (mRS).
Results: Ficolin-1 was decreased in patients compared with controls measured at 6 h (median 0.13 vs 0.33 μg/ml,
respectively, p < 0.0001). At 48 h, ficolin-1 was significantly higher (0.45 μg/ml, p < 0.0001) compared to the
6 h samples and to controls. Likewise, ficolin-2 was decreased at 6 h (2.70 vs 4.40 μg/ml, p < 0.0001) but
not at 48 h. Ficolin-3 was decreased both at 6 and 48 h (17.3 and 18.23 vs 21.5 μg/ml, p < 0.001 and <0.05,
respectively). For MBL no difference was detected between patients and controls or within patients at the
different time points. In multivariate analysis, early ficolin-1 was independently associated with unfavorable
mRS outcome (adjusted odds ratio (OR): 2.21, confidence interval (CI) 95 % 1.11–4.39, p = 0.023). Early ficolin-1
improved the discriminating ability of an outcome model including NIHSS and age (area under the curve
(AUC) 0.95, CI 95 % 0.90–0.99, p = 0.0001).
Conclusions: The ficolins are consumed within 6 h after stroke implicating activation of the LP. Early ficolin-1
is selectively related to 3-month unfavorable outcome.
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Background
Blood biomarkers may play a relevant role in early stroke
diagnosis, outcome prediction, or treatment, supporting cli-
nicians in assessing severity and predict outcome. The
quest for reliable stroke biomarkers, however, has been
quite unsatisfactory, especially in the early phase. Among
the inflammatory molecules contributing to ischemia, the
ficolins, initiators of the lectin complement pathway (LP),
may fulfill the criteria for reliable biomarkers [1, 2]. Ficolins
(ficolin-1 or M-ficolin, ficolin-2 or L-ficolin and ficolin-3 or
H-ficolin) are multimeric recognition molecules with high
sequence similarities and binding specificity for structures
exposed on the surface of pathogens and of injured
host cells. They circulate in the blood associated with
serine proteases (MASPs) and with non-enzymatic
molecules named sMAP and MAP-1 [3]. Upon bind-
ing with their targets, ficolins activate the LP, promoting
downstream complement activation. Ficolin-1 is primarily
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expressed in granulocytes and monocytes and is stored in
secretory granules from where it is exocytosed to the
bloodstream [4]. Once released, it binds back to the
membrane of the granulocytes and monocytes in a
calcium-dependent manner [5, 6]. As a consequence,
the plasma levels of ficolin-1 are relatively low (0.3 μg/ml)
[7]. Ficolin-2 and ficolin-3 are mainly produced by the
liver and liver/lung and circulate at a median level of
5 and 25 μg/ml, respectively [8, 9]. In addition to the
ficolins, three other pattern recognition molecules:
mannose-binding lectin (MBL) and the recently iden-
tified collectins: collectin-10 (CL-L1 or CL-10) and
collectin-11 (CL-K1 or CL-11) can also activate the
LP [10–12]. The plasma concentration of these mole-
cules varies among individuals, partly conditioned by
specific gene molecular variants [13–15]. They also
vary within individuals across time as a result of injury
associated LP activation/consumption [1, 2, 4, 16]. Experi-
mental and clinical evidence implicates a clear role of
the LP in the progression of brain damage in stroke,
and the data are consistent with an association of LP
activation with unfavorable outcome [1, 14, 15, 17–19],
with a few studies highlighting MBL [20, 21] and ficolin-3
[1] as independent predictors of outcome after ischemic
stroke. The role of ficolin-1 and ficolin-2 has scarcely been
studied [1, 2].
With the present study, we aimed at assessing the
prognostic value of LP measurements and to analyze
the involvement of LP after stroke in two cohorts of
patients. In one of them, we analyzed the hyperacute
changes in LP initiators. In the other, we assessed
long-term changes.
Methods
Protocol approvals and patient consents
The study involved eight Italian stroke centers, with
extensive experience in stroke diagnosis and treatment.
The study was approved by the ethics committees of
all participating centers. Written informed consent
was obtained from each patient or his/her next of kin
for the collection of data, blood samples, and subsequent
analyses according to the study protocol and local rules
(RS: 42/2011, Prot. C.E. 683/11).
Study design and cohort description
Two cohorts of patients were studied (flowchart, Fig. 1),
the first was sampled within 6 h from symptom onset
(80 patients, one recruiting center) and the second (85
patients, 8 recruiting center) was sampled longitudinally
at 48 h, at 3–5 days, and at 1 month. Inclusion criteria
were a clinical and radiologically confirmed diagnosis of
first ischemic stroke event [22], age between 16 and
80 years, and absence of known complement deficiency
(Fig. 1). Detailed demographic and clinical data, includ-
ing stroke severity (National Institutes of Health Stroke
Scale, NIHSS >14) [23] and etiology according to the
TOAST (Trial of Org 10172 in Acute Stroke Treatment)
classification [24], and conventional vascular risk factors
Fig. 1 Patient flowchart
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and treatments were collected applying a standardized
clinical form (Table 1).
Outcome evaluation, performed 3 months after stroke,
included neurological examination and stroke disability
assessment using the modified Rankin Scale (mRS,
unfavorable outcome defined by mRS >2) [25]. Outcome
was assessed by a neurologist blinded to the biochemical
determinations. Controls consisted of 61 healthy individ-
uals with no history of stroke. For each case, when
possible, a control was selected by identifying a next of
kin matched for age, race, and sex. Thirty-eight (23 %)
patients received intravenous thrombolysis according to
the European guidelines [26] and 127 (77 %) received a
conservative treatment. In all patients from 6 h cohort,
the blood sample was obtained in the hyperacute phase
of stroke before rtPA treatment.
The coordinating center (Mario Negri Insitute) was re-
sponsible to supervise data collection. The research teams
got in touch regularly (once every month) throughout the
study to discuss progresses, including recruitment, with-
drawals, and compliance. All the personnel involved fully
understood the research protocol and standard operating
procedures for the study.
Blood sampling protocol
Protocols for sample collection and handling were iden-
tical for all centers. Clotting and complement activation
were prevented by collecting samples in 10 mM of ethyl-
enediaminetetraacetic acid (EDTA). Plasma was proc-
essed at 2000 g for 15 min at 4 °C and stored locally at
each center at −80 °C before analysis. For myeloperoxi-
dase (MPO) quantification, an additional centrifugation
step was performed in order to avoid contamination
with platelets and white blood cells. Analysis of plasma
samples was centralized and performed at the University
of Copenhagen and at the Mario Negri Institute. All
plasma samples were thawed only once prior to use.
Protein quantification
Ficolin-1, -2, and -3 and MBL assays were routinely deter-
mined by sandwich ELISAs using specific in-house pro-
duced monoclonal antibodies as previously described
[7–9, 27]. All assays were optimized for automated
analysis in the 384-well format on Biomek FX (Beckman
Coulter, Fullerton, CA,USA) [25]. MPO was measured by
a commercially available ELISA kit [28]. C-reactive protein
(CRP) was determined by automated latex-enhanced im-
munoassay. Elevated baseline CRP (>3.0 mg/l) was used
as marker of increased risk of sepsis [29].
Other assays
D-dimer was assessed by automated latex-enhanced
immunoassay [30]. Leukocyte count, percentage of neu-
trophils, percentage of lymphocytes, and neutrophils to
lymphocytes ratio (N/L ratio) were determined on admis-
sion to the emergency department and within 24 h of the
onset in 81.2 % of cases.
Statistical analyses
Plasma concentration of complement components did
not follow a normal distribution (p > 0.05, Shapiro-Wilk
test). The two cohorts of patients were studied by indirect
comparison analysis. Categorical variables were expressed
as number of patients and proportions. Continuous vari-
ables were expressed as median and interquartile range
(IQR) or mean and standard deviation (SD).




6 h (n = 80) 48 h (n = 85)
Demographic characteristics
Age≥ 50 years, n (%) 52 (85) 75 (94) 73 (86)
Gender, (M/F) 26/35 33/47 49/36
Race caucasian, n (%) 61 (100) 80 (100) 82 (96)
Risk factors, n (%)
Hypertension 15 (24) 60 (75)***, # 60 (70)**
Diabetes 3 (5) 11 (14) 29 (34)***, ##
Dyslipidemia 12 (20) 43 (54)*** 39 (46)
Cardiovascular diseases 2 (3) 24 (30)*** 19 (22)
Atrial fibrillation 2 (3) 30 (37)*** 15 (18)*
Smoking history 22 (37) 21 (26) 44 (57)
Recent Infections 2 (3) – 1 (1)
CRP≥ 3 mg/l – 5 (6) 16 (19)
Clinical characteristics
TOAST classification, n (%)
Cardioembolism 24 (30) 23 (27)
Atherosclerosis 21 (26) 33 (39)
Small vessel occlusion 11 (14) 6 (7)
Undetermined etiology 24 (30) 22 (25)
Other determined etiology – 2 (2)
NIHSS, median (IQR) 5 (2–11) 5 (2–11)
Severe (>14), n (%) 12 (16) 14 (17)
3-month mRS, median (IQR) 2 (1–4) 1 (0–3)
mRS (>2), n (%) 33 (41) 36 (42)
Mortality 10 (12) 2 (3)
Categorical variables are presented as number of patients with/without
percentages in parentheses; continuous variables as median with interquartile
range (IQR). Age was dichotomized using 50 years as cut-off (based on the
minimum quartile in control group)
TOAST Trial of Org 10172 in Acute Stroke Treatment, NIHSS National
Institutes of Health Stroke Scale, 3-month mRS 3-month modified Rankin
Scale, CRP C-reactive protein
*<0.05, **<0.01, ***<0.001, vs control group by univariate and #<0.05, ##<0.01
by multivariate logistic regression analysis
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Univariate analysis
Baseline demographic and clinical characteristics between
cases and controls and between patients were examined
by means of the Fisher exact test for categorical variables
and the Mann-Whitney U test for continuous variables.
Age was analyzed as a continuous variable. The differ-
ences between groups and time points were compared
using the Kruskal-Wallis test followed by Dunn post hoc
test. Interactions between LP initiators and the potential
confounders were examined by Wilcoxon-Mann-Whitney
test and Spearman’s rank correlation coefficient (rho) for
bivariate correlations between ficolin-1 and inflammatory
markers.
Multivariate regression models and C-statistics
Multivariate analysis was performed by binary logistic
regression analysis, including established risk factors
and outcome predictors showing a significant univariate
association. Significant predictors were tested for inter-
action, based on biological plausibility and on factors that
might influence the prognostic value of LP initiators. The
overall diagnostic accuracy of LP initiators was assessed
with the area under the receiver operating characteristic
(ROC) curve (AUC), with cut-offs obtained by pooling
values for patients and controls. To examine whether the
addition of LP markers improved the predictability of the
clinical model for stroke outcome, a regression analysis by
entering individual or a combined set of variables into the
baseline clinical model (combined model assessed adjust-
ing predicted values) was performed. The analysis was
performed using age and NIHSS score as continuous
variables. Odds ratio (OR) with 95 % confidence intervals
(CI 95 %) was reported as measures of association. To
account for data missing to follow-up, an additional ana-
lysis was performed assuming the “worst mRS scenario”
for patients missing the 3-month evaluation. Statistical
analysis was performed using Prism 5 (GraphPad software,
San Diego, CA); SPSS 20.0 (SPSS Inc., Chicago, IL, USA),
and SAS 9.2 (SAS Institute Inc., Cary, NC, USA).
Results
Baseline demographic and clinical characteristics
Patient enrollment and follow-up details are outlined in
the flowchart (Fig. 1). The 3-month follow-up was re-
corded in 158 (96 %) patients. Mean age was 70 ± 13
(mean ± SD), and 50 % of patients were female. The
median NIHSS was 9 (IQR 6–15), the median 3-month
mRS and mortality were respectively 1 (IQR 0–4) and 11
(7 %). All demographic and clinical features of included
patients from the two cohorts and controls are sum-
marized in Table 1. As expected, at univariate analysis
hypertension, diabetes, dyslipidemia, cardiovascular dis-
eases, and atrial fibrillation were significantly more fre-
quent in stroke patients than in controls (Table 1 and
Additional file 1: Table S1). Missing values were as follows:
smoking history, n = 2 (3 %) in controls and n = 8 (9 %) in
patients enrolled within 48 h; NIHSS score, n = 3 (4 %);
and mRS score, n = 7 (8 %), only in patients enrolled
within 48 h. Possible confounding factors between the
two cohorts were analyzed by multivariate analysis.
The results showed similar sex predominance, stroke sever-
ity, stroke etiology, atrial fibrillation, functional outcome,
and mortality and highlight differences for the prevalence
of diabetes, smoking history, and elevated baseline C-
reactive protein (Additional file 2: Table S2.1). Thus, we
assessed possible changes in LP activators associated with
these confounding factors (Additional file 2: Table S2.2).
Notably, no interactions were found between ficolin-1 and
the potential confounders. High ficolin-3 was associated
with smoking history (nonsmokers vs smokers: 16.48 vs
20.15 ng/ml, p = 0.015), but multivariate analysis revealed
no association between smoking and functional outcome
(Table 2).
LP initiators in healthy controls and acute ischemic stroke
patients
Plasma levels of ficolin-1 were significantly lower in
patients compared to controls when measured within
6 h (median 0.13 vs 0.33 μg/ml, respectively, p < 0.0001;
Fig. 2a). At 48 h, ficolin-1 levels were significantly higher
(0.45 μg/ml; Fig. 2a) compared to the 6 h cohort and to
controls. Ficolin-2 levels were decreased at 6 h, but not
at 48 h after stroke, in patients versus controls (2.70 vs
4.40 μg/ml, respectively, p < 0.0001; Fig. 2b). Ficolin-3
levels were significantly lower both at 6 and 48 h (patients:
17.30 and 18.23 vs controls: 21.50 μg/ml, p < 0.001 and
<0.05, respectively; Fig. 2c). Twenty-two patients (13 %)
and five controls (8 %) had MBL levels <100 ng/ml, a
value associated with MBL deficiency [31]. Grouping pa-
tients according to this cut-off resulted in no differences
in demographics and clinical characteristics (data not
shown). No significant differences were detected for MBL
levels between patients at 6 and 48 h and controls
(patients: 1081 and 1085 vs controls: 1060 ng/ml, p > 0.05,
respectively; Fig. 2d).
The time-course analysis showed that the increased
ficolin-1 concentrations persisted at least up to 3–5 days
after stroke (controls: 0.33 vs patients: 0.47 μg/ml, p <
0.01; Fig. 2a) with no changes in the other LP initiators.
Admission levels of ficolins and MBL were not related
to initial stroke severity, defined according to the NIHSS
score, or to different stroke etiology (data not shown).
Diagnostic accuracies of LP initiators for discriminating
stroke patients from controls
We found that the AUCs of ficolin-1 and ficolin-3 had good
diagnostic accuracy (ficolin-1: 0.91, p < 0.0001; ficolin-3:
0.68, p < 0.001; Fig. 3a, b). However, early ficolin-1 was
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significantly better in discriminating the ischemic condition
compared to delayed ficolin-1 or ficolin-3 values (Fig. 3b).
The optimal cut-off value of ficolin-1 as a diagnostic
marker of stroke was projected to be 0.25 μg/ml, which
yielded a sensitivity of 87 % and a specificity of 84 %; at this
cut-off, the odds ratio (OR) was 35.19 [95 % confidence
intervals (CI 95 %) 13.63–90.86, p < 0.0001].
Prediction of functional outcome at 3 months
A total of 69 patients (43 %) had an unfavorable out-
come at 3 months. In the univariate model, 6 h ficolin-1
(OR 1.73, CI 95 % 1.03–2.91, p = 0.039), age (OR 1.10,
CI 95 % 1.03–1.17, p = 0.003), and NIHSS score (OR
1.17, CI 95 %: 1.06–1.29, p = 0.002) were associated with
unfavorable outcome. Subsequent multivariate analysis
demonstrated that 6 h ficolin-1 was independently pre-
dictive of an unfavorable outcome after adjustment for
all other significant outcome predictors (adjusted OR
2.21, CI 95 % 1.11–4.39, p = 0.023; Table 2). The addition
of 6 h ficolin-1 to a combined clinical model including
NIHSS score and age further improved the discrimin-
atory accuracy of the NIHSS [AUC 0.93(CI 95 %
0.87–0.98), p = 0.0001; AUC of the NIHSS 0.87 (CI
95 % 0.77–0.96); Fig. 4a, b]. Notably, 6 h ficolin-1 had a
similar crude prognostic accuracy as compared with the
reference markers of functional outcome CRP and D-
dimer [32] (Additional file 3: Table S3). When measured
at 48 h, ficolin-1 was no longer associated with unfavor-
able outcome whereas NIHSS score was found to be
predictive of long-term functional outcome (Table 2).
Seven patients were lost to follow-up; assuming that these
patients had the worst scenario, no changes were found in
ficolin levels (Additional file 4: Table S4).
Because peripheral blood cells of myeloid lineage are
the first source of circulating ficolin-1 [6, 33–35], we mea-
sured MPO as marker of secretory vesicle mobilization
[6]. In stroke patients, MPO levels at 6 h where not
different compared to controls (57.99 vs 45.95 ng/ml,
respectively, p > 0.05; Fig. 5a). Notably, MPO levels
were higher in 48 h than in 6 h patients (79.20 vs
57.99 ng/ml, p < 0.05; Fig. 5a). Ficolin-1 MPO correl-
ation was not present at 6 h, but a slight correlation
was observed at 48 h (r = 0.25, p = 0.02; Fig. 5b). In
accordance with this, 48 h ficolin-1 values were signifi-
cantly correlated with total leukocyte count (p = 0.008),
neutrophil count, and N/L ratio (p = 0.08), whereas lym-
phocytes were negatively correlated (p = 0.003; Additional
file 5: Table S5). A total of 12 patients (7 %) died within
3 months after stroke. Due to the low number of deaths,
the overall predictive value ability of ficolin-1 to distinguish
survivors from non-survivors could not be estimated.
Discussion
The LP, now recognized to be at the crossroad between
complement and coagulation, is known to be deeply
involved in the pathophysiology of brain ischemic injury
[1, 2, 14, 15, 17, 20, 21, 36]. The present multicenter
observational study shows that LP in plasma is already
consumed 6 h following stroke, consistent with LP acti-
vation, and that among the LP initiators evaluated in this
study, ficolin-1 is selectively related to an unfavorable
outcome 3 months after ischemic stroke. Our data
Table 2 Univariate and multivariate predictors of functional outcome
6 h 48 h
Univariate Multivariate Univariate Multivariate
OR (CI 95 %) p OR (CI 95 %) p OR (CI 95 %) p OR (CI 95 %) p
Predictors
Age 1.10 (1.03–1.17) 0.003 1.11 (1.04–1.19) 0.003 1.0 (0.96–1.04) 0.79 – –
Gender 1.53 (0.60–3.90) 0.38 – – 0.92 (0.36–2.39) 0.87 – –
Hypertension 1.76 (0.59–5.27) 0.31 – – 0.37 (0.13–1.02) 0.054 – –
Diabetes 1.48 (0.39–5.61) 0.56 – – 1.51 (0.57–3.98) 0.40 – –
Dyslipidemia 0.80 (0.32–1.98) 0.63 – – 0.68 (0.26–1.75) 0.42 – –
Cardiovascular diseases 0.60 (0.22–1.65) 0.33 – – 1.23 (0.27–5.58) 0.79 – –
Atrial fibrillation 2.17 (0.84–5.60) 0.11 – – 1.0 (0.30–3.30) 1.0 – –
Smoking history 0.44 (0.15–1.25) 0.19 – – 1.08 (0.38–3.07) 1.0 – –
Toast classification 0.68 (0.46–1.01) 0.055 – – 1.08 (0.81–1.43) 0.59 – –
NIHSS 1.17 (1.06–1.29) 0.002 1.17 (1.05–1.31) 0.005 1.14 (1.05–1.24) 0.002 1.14 (1.05–1.24) 0.002
Ficolin-1a 1.73 (1.03–2.91) 0.039 2.21 (1.11–4.39) 0.023 0.52 (0.03–9.08) 0.65 – –
Ficolin-3 0.99 (0.93–1.05) 0.76 – – 0.93 (0.85–1.01) 0.11 – –
Exact p value for univariate and multivariate logistic regression analysis is reported
CI 95 % 95 % confidence interval, OR odds ratio, NIHSS National Institutes of Health Stroke Scale, 3-month mRS 3-month modified Rankin Scale
aNote that the odds ratio corresponds to a 0.1 unit change in the explanatory variable
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demonstrate for the first time that ficolin-1 is an in-
dependent predictor of functional outcome capable of
improving the discriminatory ability of the NIHSS
and of age in a combined prognostic model. Ficolin-1
is a recently identified LP activator. It is synthesized
and presented on the surface of peripheral monocytes
and neutrophils, possibly promoting neutrophil adhesion,
aggregation, and migration [4, 6, 33–35, 37]. Because of
these characteristics, ficolin-1 might play a role in ische-
mic damage; however, no data were available up to now in
stroke patients. As a possible consequence of its presence
on cells, its circulating levels are relatively low [7, 38].
Fig. 2 LP initiators at early and late time points. Plasma concentrations of ficolin-1 (a), ficolin-2 (b), ficolin-3 (c), and MBL (d) in controls (n = 61)
and in two different group of stroke patients sampled at different time points after stroke (n = 80 patients within 6 h and n = 85 within 48 h). In
the latter group, blood samples were collected at baseline, at days 3–5 (n = 78) and at 1 month (n = 60) after stroke. The dotted red line indicates
the median value in controls. Data are expressed as median with interquartile range. p values *<0.05, **<0.01, ***<0.001, ****<0.0001 versus control
and among groups, Kruskal-Wallis test with Dunn post hoc test
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Consistently with previous data [7], our results show that
in healthy subjects, ficolin-1 circulates in plasma and is
present at a median concentration of 0.33 μg/ml. Com-
pared to controls, ficolin-1 levels are significantly lower
when measured within 6 h after stroke and significantly
higher when measured at longer time points, up to 3–
5 days. It can be hypothesized that at the early time point,
when plasma ficolin-1 levels are associated to 3-month
outcome, consumption exceeds production/release and
plasma levels essentially reflect the degree of local brain
inflammatory response [33]. Later on, when ficolin-1 pro-
duction/release exceeds consumption, the plasma concen-
tration increases. The lack of association between ficolin-1
and the NIHSS, an index of neurological impairment,
suggests that, besides the degree of initial injury, an over-
whelming acute inflammatory host response significantly
contributes to the pathogenesis of stroke and long-term
outcome. Interestingly, at late sampling time point (from
48 h on), but not earlier, ficolin-1 correlates with MPO
suggesting that at this later stage, both parameters reflect
the overall leukocyte activation. This is also mirrored by
the correlation with the neutrophil count at the same late
sampling time. Not surprisingly, at this time point, ficolin-
1 has lost its prognostic value. This indicates that ficolin-1
behavior is not the typical one of an acute phase protein.
A similar behavior in a different contest has been reported
in patients undergoing colorectal cancer surgery who dis-
play an early reduction of ficolin-1, followed by a rebound
at longer time points (up to 2 weeks) with no relation to
CRP changes [38].
As compared to healthy subjects, ficolin-2 plasma levels
were significantly lower in stroke patient samples obtained
within 6 h after the onset of symptoms. This finding is
similar to that reported by Füst and collaborators 8 h after
stroke [1]. They showed decreased ficolin-2 levels that
persisted up to 3 days even though with a high variability.
In our study, 3–5 days samples revealed a complete recov-
ery to normal values. Interestingly, an early decrease in
ficolin-2 was also observed in subarachnoid hemorrhage
patients [2]. In the present study, ficolin-2 levels were not
associated with stroke severity indicating that this protein
may be related to a systemic inflammatory response rather
than to local brain events.
We observed also an early and persistent consumption
of ficolin-3. This is in agreement with previous obser-
vations [1]. This LP activator shows a significant diag-
nostic accuracy in discriminating patients from controls,
although to a lower extent than ficolin-1. The prolonged
reduction suggests that in these patients, ficolin-3 is used
over time. Ficolin-3 was previously reported to be associ-
ated with an unfavorable prognosis when assessed at days
3–4, but not at 8 h [1]. A recent study shows that ficolin-3
functional LP activity, but not its levels, was associated
with unfavorable outcome in subarachnoid hemorrhage
patients [2]. The discrepancies between the different stud-
ies are not clear and could indicate heterogeneity or subtle
clinical differences between the different cohorts. Never-
theless, taken together, these data implicate a role for
ficolin-3 in stroke although its specific prognostic value
still needs to be clarified.
In line with the reported prevalence [13], approximately
13 % of our patients show low MBL concentrations
(<100 ng/ml). The clinical characteristics of patients with
MBL <100 ng/ml and those with levels >100 ng/ml did
not differ, and we did not find evidence of MBL changes
related to stroke severity or outcome. Genetically defined
Fig. 3 Diagnostic accuracy of ficolin-1 and ficolin-3 in discriminating stroke patients from controls. ROC curve of early ficolin-1 levels (6 h)
demonstrating sensitivity as a function of 1-specificity for discriminating case/control status at the early time point (a). ROC analysis data,
including optimal cut-offs, of ficolin-1 and ficolin-3 for discriminating case/control status at early and late time points (b). The AUC and
exact p value for asymptotic significance are reported. SE sensitivity, SP specificity, AUC area under the curve, CI 95 % 95 % confidence
interval, OR odds ratio. aThe odds ratio corresponds to a unit change in the explanatory categorical variables
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MBL deficiency has been associated with a better outcome
after stroke [14, 15]. Consistently, MBL production has
been correlated with increased risk of acute stroke [36],
morbidity, and mortality after stroke [20, 21]. The circu-
lating levels measured here, being the result of a balance
between genetic and pathophysiological conditions, may
conceal the actual relationship between MBL and stroke.
The lack of correlation could indicate that previous ob-
served associations with MBL are related to heterogeneity
among different stroke cohorts. Thus, further studies, in-
cluding the detection of genotype of the patients are
necessary to elucidate the role of MBL in the pathogenesis
of stroke. Nevertheless, the available studies indicate that
the different LP molecules emerge as sensitive biomarkers,
which may reflect underlying pathophysiology and out-
come of subarachnoid hemorrhage and ischemic stroke.
This study has some limitations. First, the plasma
samples analyzed were obtained from two cohorts with
different sampling time (within 6 h in the first group
and within 48 h in the other one). The investigation of
different patients at different times was simply due to
the participation of the Emergency Room staff (the one
charged with 6 h sampling), which could be confirmed
only in one center. Thus, the indirect comparison allows
only to hypothesize the temporal changes of ficolin
levels within 48 h after stroke onset. A confirmatory lon-
gitudinal study with a larger sample size will be therefore
necessary to exactly define the window of interest of
ficolin-1 changes. The short-term changes over time were
not available to test intra-individual time trends. In
addition, it should be mentioned that we did not analyze
the significance of LP initiators in patients undergoing
thrombolysis since our study was underpowered to meet
this aim. A dedicated study should be performed to under-
stand if and how thrombolytics may affect lectin protein
consumption.
Conclusions
In conclusion, our study shows that the ficolins are
consumed within 6 h after ischemic stroke and identifies
Fig. 4 Prognostic accuracies of early ficolin-1 as predictor of
unfavorable outcome. ROC curve of early ficolin-1 levels (6 h)
demonstrating sensitivity as a function of 1-specificity for predicting
functional outcome at 3 months, based on the logistic model
incorporating the relative contribution of each predictor in the
combined model (ficolin-1 adjusted predictive values for NIHSS and
age (a). The AUC and exact p value for asymptotic significance are
reported (b). AUC area under the curve, CI 95 % 95 % confidence
interval, NIHSS National Institutes of Health Stroke Scale
Fig. 5 MPO levels at early and late time points in stroke patients
and controls. Plasma concentrations of MPO in controls and patients
with stroke (sampled within 6 h and 48 h, respectively). Data are
expressed as median with interquartile range. p values *<0.05
versus control and among groups, Kruskal-Wallis test with Dunn
post hoc test (a). Spearman’s rho for ficolin-1 versus MPO (b).
MPO myeloperoxidase
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for the first time ficolin-1 as a sensitive prognostic
marker for stroke. Ischemic stroke is a heterogeneous
disorder, and efforts are needed to better define its
molecular biology. The available data indicate that LP is
involved to a different extent and with distinctive func-
tions over time in ischemic and hemorrhagic stroke. We
now provide evidence of a specific role for ficolin-1
showing higher sensitivity compared to the other LP
activators towards stroke outcome.
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